Kiora Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Preferred Stock Series C Preferred Stock	Preferred Stock Series D Preferred Stock	Preferred Stock	Common Stock Series C Preferred Stock	Common Stock Series D Preferred Stock	Common Stock Private Placement	Common Stock Registered direct offering	Common Stock	Additional Paid-In Capital Series C Preferred Stock	Additional Paid-In Capital Series D Preferred Stock	Additional Paid-In Capital Private Placement	Additional Paid-In Capital Registered direct offering	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Private Placement	Registered direct offering	Total
Balance at Dec. 31, 2019			$ 41					$ 40,778					$ 106,689,065	$ 139,465	$ (100,246,894)			$ 6,622,455
Balance (in shares) at Dec. 31, 2019			4,092					4,077,755
Stock-Based Compensation													723,856					723,856
Issuance of Common Stock from Warrants, Net								$ 454					217,546					218,000
Issuance of Common Stock from Warrants, Net (in shares)								45,417
Issuance of Common Stock in Offerings, Net of Offering Costs								$ 5,000					4,496,313					4,501,313
Issuance of Common Stock in Offerings, Net of Offering Costs (in shares)								500,000
Shares Issued to Panoptes Stockholders at Acquisition								$ 8,842					4,657,312					4,666,154
Shares Issued to Panoptes Stockholders at Acquisition (in shares)			46					884,222
Dissolution of Foreign Entity														(113,717)				(113,717)
Issuance of Common Stock from Restricted Stock Award Grants								$ 490					(490)
Issuance of Common Stock from Restricted Stock Award Grants (in shares)								49,000
Foreign Currency Translation Adjustment														(26,550)				(26,550)
Net Loss															(6,861,770)			(6,861,770)
Balance at Dec. 31, 2020			$ 41					$ 55,564					116,783,602	(802)	(107,108,664)			9,729,741
Balance (in shares) at Dec. 31, 2020			4,138					5,556,394
Balance at Dec. 31, 2020			$ 41					$ 55,564					116,783,602	(802)	(107,108,664)			9,729,741
Balance (in shares) at Dec. 31, 2020			4,138					5,556,394
Balance at Dec. 31, 2020			$ 41					$ 55,564					116,783,602	(802)	(107,108,664)			9,729,741
Balance (in shares) at Dec. 31, 2020			4,138					5,556,394
Balance at Dec. 31, 2020			$ 41					$ 55,564					116,783,602	(802)	(107,108,664)			9,729,741
Balance (in shares) at Dec. 31, 2020			4,138					5,556,394
Stock-Based Compensation													842,475					842,475
Issuance of Common Stock from Warrants, Net								$ 104					49,897					50,001
Issuance of Common Stock from Warrants, Net (in shares)								10,417
Conversion of Preferred Stock into Common Stock	$ (41)			$ 8,525	$ 109				$ (8,484)	$ (109)
Conversion of Preferred Stock into Common Stock (in shares)	(4,092)	(39)		852,500	10,911
Issuance of Common Stock in Offerings, Net of Offering Costs						$ 15,311	$ 46,689				$ 7,973,550	$ 9,709,659				$ 7,988,861	$ 9,756,348
Issuance of Common Stock in Offerings, Net of Offering Costs (in shares)						1,531,101	4,668,844
Shares issued to Bayon Shareholders at Acquisition								$ 338					67,598					67,936
Shares issued to Bayon Shareholders at Acquisition (in shares)								33,798
Dissolution of Foreign Entity																		0
Foreign Currency Translation Adjustment														(85,629)				(85,629)
Net Loss															(13,770,685)			(13,770,685)
Balance at Dec. 31, 2021			$ 0					$ 126,640					$ 135,418,188	$ (86,431)	$ (120,879,349)			$ 14,579,048
Balance (in shares) at Dec. 31, 2021			7					12,663,965